Whitefort Capital Management Increases Stake in Arbutus Biopharma to 8.1%

On April 13, 2026, Whitefort Capital Management, LP and its affiliates filed an amendment to their Schedule 13D regarding Arbutus Biopharma Corp (ABUS). The filing reports that Whitefort Capital Master Fund, LP increased its position to 15,794,261 common shares, representing approximately 8.1% of the company based on 195,478,068 shares outstanding as of March 18, 2026. This reflects an increase from the previously reported 13,343,228 shares. The acquisitions were made through a series of open-market purchases between March 3, 2026, and April 10, 2026, at prices ranging from approximately $4.12 to $4.25 per share. The aggregate purchase price for the total holdings is approximately $41,839,734, funded via working capital. Reporting persons including Whitefort Capital GP, LLC, Whitefort Capital Management GP, LLC, David Salanic, and Joseph Kaplan share beneficial ownership of these shares through their respective roles as general partners and managing members within the Whitefort entity structure.